Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Valneva SE ADR (VALN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: VALN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.89
1 Year Target Price $12.89
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 9.46% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 844.65M USD | Price to earnings Ratio - | 1Y Target Price 12.89 |
Price to earnings Ratio - | 1Y Target Price 12.89 | ||
Volume (30-day avg) 4 | Beta 1.19 | 52 Weeks Range 4.20 - 12.25 | Updated Date 01/9/2026 |
52 Weeks Range 4.20 - 12.25 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -56.78% | Operating Margin (TTM) -126.99% |
Management Effectiveness
Return on Assets (TTM) -9.64% | Return on Equity (TTM) -55.53% |
Valuation
Trailing PE - | Forward PE 666.67 | Enterprise Value 899862802 | Price to Sales(TTM) 4.69 |
Enterprise Value 899862802 | Price to Sales(TTM) 4.69 | ||
Enterprise Value to Revenue 4.32 | Enterprise Value to EBITDA 26.94 | Shares Outstanding 86044586 | Shares Floating 147500947 |
Shares Outstanding 86044586 | Shares Floating 147500947 | ||
Percent Insiders - | Percent Institutions 6.14 |
Upturn AI SWOT
Valneva SE ADR
Company Overview
History and Background
Valneva SE is a European biotechnology company focused on vaccines for infectious diseases. It was formed in 2013 through the merger of Vivalis and Intercell. The company has since focused on developing and commercializing its vaccine pipeline, with significant milestones including the development of its COVID-19 vaccine, VLA2001, and its Lyme disease vaccine candidate, VLA15.
Core Business Areas
- Vaccine Development and Commercialization: Valneva's primary focus is on the development, manufacturing, and commercialization of innovative vaccines for infectious diseases. This includes both established vaccines and novel vaccine candidates targeting unmet medical needs.
- Infectious Disease Vaccines: The company is actively developing vaccines for other infectious diseases, with a notable focus on Lyme disease and COVID-19.
- Traveler's Vaccines: Valneva has a portfolio of vaccines for travelers, including vaccines against Japanese encephalitis (IXIAROu00ae) and tick-borne encephalitis (TBE).
Leadership and Structure
Valneva SE is a publicly traded company headquartered in Saint-Herblain, France. It is led by a management board and overseen by a supervisory board. Key leadership positions include CEO, CFO, and heads of R&D and Commercial Operations.
Top Products and Market Share
Key Offerings
- Description: A vaccine for active immunization against Japanese encephalitis virus (JEV) infection. Competitors include other JEV vaccines available in specific regions.
- Market Share: Specific market share data is proprietary and not publicly disclosed, but it is a key product in its travel vaccine segment.
- Product Name 1: IXIAROu00ae (Japanese Encephalitis Vaccine)
- Description: A prophylactic vaccine candidate for Lyme disease targeting the OspA protein of Borrelia burgdorferi. This is currently in late-stage clinical trials. Competitors include companies researching or developing Lyme disease vaccines, such as Pfizer/BioNTech.
- Market Share: Currently in development, market share is not applicable. If approved, it would aim to capture a significant portion of the potential Lyme disease vaccine market.
- Product Name 2: VLA15 (Lyme Disease Vaccine Candidate)
- Description: An inactivated whole-virus COVID-19 vaccine. Valneva has experienced fluctuations in its COVID-19 vaccine program due to market dynamics and regulatory approvals. Competitors include major COVID-19 vaccine producers like Pfizer, Moderna, AstraZeneca, and Johnson & Johnson.
- Market Share: Market share has been subject to global demand and regional regulatory decisions. Valneva has faced challenges in securing large-scale orders compared to mRNA vaccines.
- Product Name 3: VLA2001 (COVID-19 Vaccine)
Market Dynamics
Industry Overview
The vaccine market is a significant and growing sector within the pharmaceutical industry, driven by increasing awareness of infectious diseases, government immunization programs, and the development of novel vaccine technologies. The market is highly competitive and regulated.
Positioning
Valneva positions itself as a specialist vaccine company focusing on both established travel vaccines and the development of innovative vaccines for unmet medical needs. Its strengths lie in its differentiated vaccine technologies and its focus on specific disease areas.
Total Addressable Market (TAM)
The TAM for vaccines is substantial and multi-billion dollar, encompassing global immunization needs for infectious diseases. Valneva's TAM is a subset of this, focusing on specific vaccine segments like Japanese encephalitis, tick-borne encephalitis, Lyme disease, and potentially other emerging infectious diseases. Its current positioning is that of a niche player with potential for significant growth if its pipeline products are successful.
Upturn SWOT Analysis
Strengths
- Established expertise in vaccine development and manufacturing.
- Portfolio of commercialized travel vaccines (e.g., IXIAROu00ae).
- Promising late-stage Lyme disease vaccine candidate (VLA15).
- Focus on differentiated vaccine technologies.
Weaknesses
- Limited revenue diversification compared to larger pharmaceutical companies.
- Dependence on the success of its clinical-stage pipeline.
- Historically smaller market share in broader vaccine segments.
- Need for significant capital investment for late-stage development and commercialization.
Opportunities
- Increasing global demand for effective vaccines.
- Potential approval and commercialization of VLA15 for Lyme disease, a significant unmet medical need.
- Partnerships and collaborations for vaccine development and distribution.
- Expansion into new geographical markets.
- Addressing emerging infectious disease threats.
Threats
- Regulatory hurdles and lengthy approval processes for new vaccines.
- Intense competition from established vaccine manufacturers.
- Challenges in securing large-scale manufacturing and distribution agreements.
- Public perception and vaccine hesitancy.
- Changes in global health priorities and funding.
Competitors and Market Share
Key Competitors
- Pfizer Inc. (PFE)
- Moderna, Inc. (MRNA)
- Sanofi S.A. (SNY)
- GSK plc (GSK)
Competitive Landscape
Valneva operates in a highly competitive vaccine market dominated by larger pharmaceutical companies with extensive R&D budgets, established distribution networks, and diverse product portfolios. Valneva's advantage lies in its specialization and focus on specific, often unmet, vaccine needs, such as Lyme disease. However, it faces challenges in competing for market share and securing large-scale partnerships against industry giants.
Growth Trajectory and Initiatives
Historical Growth: Valneva's historical growth has been marked by strategic mergers, pipeline development, and securing partnerships. The company has transitioned from a focus on a few established vaccines to building a more robust pipeline of novel vaccine candidates. The COVID-19 pandemic presented both an opportunity and a challenge that significantly impacted its growth trajectory.
Future Projections: Future growth projections for Valneva are heavily dependent on the successful development and commercialization of its key pipeline candidates, particularly VLA15 (Lyme disease). Analyst estimates will vary based on the perceived probability of regulatory approval and market uptake of these products. Positive clinical trial results and regulatory approvals are key drivers for projected growth.
Recent Initiatives: Recent initiatives include advancing VLA15 through Phase 3 clinical trials, potential strategic partnerships for VLA15's commercialization, and continued optimization of its manufacturing capabilities. The company has also been evaluating its COVID-19 vaccine strategy in light of evolving market conditions.
Summary
Valneva SE ADR is a specialized vaccine company with a promising pipeline, particularly its Lyme disease vaccine candidate, VLA15. Its strengths lie in its focused R&D and existing travel vaccine portfolio. However, it faces significant competition and reliance on the success of its late-stage development programs. The company needs to navigate regulatory complexities and secure strong commercial partnerships to translate its pipeline potential into sustainable revenue growth and profitability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company financial reports (SEC filings)
- Industry research reports
- Financial news outlets
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Valneva SE ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-05-05 | President, CEO & Director Mr. Thomas Lingelbach | ||
Sector Healthcare | Industry Biotechnology | Full time employees 713 | Website https://valneva.com |
Full time employees 713 | Website https://valneva.com | ||
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. The company was founded in 1998 and is based in Saint-Herblain, France.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.